AIM: To assess whether immunohistochemically stained tissue microarrays (TMA) of 2 mm cores from paraffin embedded tumour tissue may replace whole sections in semi-quantitative evaluation of selected potential markers for endocrine treatment. METHODS: Whole sections and 2 mm cores on TMA were used for immunohistochemical staining of potential markers for endocrine treatment. The Allred scoring system was used for the markers with nuclear localisation: the oestrogen receptor, the progesterone receptor, p27 and the oestrogen receptor co-regulator amplified in breast cancer 1 (AIB1). The Allred scoring system was also used for the non-nuclear markers Bcl-2, pS2 and cyclooxygenase 2 (COX-2); the membrane receptors HER-2, insulin-like growth factor I receptor (IGF-IR) and epidermal growth factor receptor were quantified according to the guidelines for the Herceptest. RESULTS: The data and statistical analyses showed that the semi-quantitative evaluation of oestrogen receptor, progesterone receptor, AIB1, COX-2, HER-2 and IGF-IR on TMA blocks was comparable with analysis on whole sections. CONCLUSIONS: This study shows that semi-quantitative scoring of 2 mm cores on TMA is feasible for several potential markers for endocrine therapy. Considering the small size of many breast tumours, the speed and cost-effectiveness of immunohistochemistry on TMA compared with whole sections, and the importance of the expression level of the proteins, semi-quantitative scoring on TMA has great potential in both retrospective and prospective studies aiming at improving the prediction of response to endocrine treatment.
AIM: To assess whether immunohistochemically stained tissue microarrays (TMA) of 2 mm cores from paraffin embedded tumour tissue may replace whole sections in semi-quantitative evaluation of selected potential markers for endocrine treatment. METHODS: Whole sections and 2 mm cores on TMA were used for immunohistochemical staining of potential markers for endocrine treatment. The Allred scoring system was used for the markers with nuclear localisation: the oestrogen receptor, the progesterone receptor, p27 and the oestrogen receptor co-regulator amplified in breast cancer 1 (AIB1). The Allred scoring system was also used for the non-nuclear markers Bcl-2, pS2 and cyclooxygenase 2 (COX-2); the membrane receptors HER-2, insulin-like growth factor I receptor (IGF-IR) and epidermal growth factor receptor were quantified according to the guidelines for the Herceptest. RESULTS: The data and statistical analyses showed that the semi-quantitative evaluation of oestrogen receptor, progesterone receptor, AIB1, COX-2, HER-2 and IGF-IR on TMA blocks was comparable with analysis on whole sections. CONCLUSIONS: This study shows that semi-quantitative scoring of 2 mm cores on TMA is feasible for several potential markers for endocrine therapy. Considering the small size of many breast tumours, the speed and cost-effectiveness of immunohistochemistry on TMA compared with whole sections, and the importance of the expression level of the proteins, semi-quantitative scoring on TMA has great potential in both retrospective and prospective studies aiming at improving the prediction of response to endocrine treatment.
Authors: Elizabeth Half; Xi Ming Tang; Karin Gwyn; Aysegul Sahin; Kyle Wathen; Frank A Sinicrope Journal: Cancer Res Date: 2002-03-15 Impact factor: 12.701
Authors: M J Ellis; A Coop; B Singh; L Mauriac; A Llombert-Cussac; F Jänicke; W R Miller; D B Evans; M Dugan; C Brady; E Quebe-Fehling; M Borgs Journal: J Clin Oncol Date: 2001-09-15 Impact factor: 44.544
Authors: A M Brodie; Q Lu; B J Long; A Fulton; T Chen; N Macpherson; P C DeJong; M A Blankenstein; J W Nortier; P H Slee; J van de Ven; J M van Gorp; J R Elbers; M E Schipper; G H Blijham; J H Thijssen Journal: J Steroid Biochem Mol Biol Date: 2001-12 Impact factor: 4.292
Authors: S Thrane; A M Pedersen; M B H Thomsen; T Kirkegaard; B B Rasmussen; A K Duun-Henriksen; A V Lænkholm; M Bak; A E Lykkesfeldt; C W Yde Journal: Oncogene Date: 2014-11-03 Impact factor: 9.867
Authors: B Ejlertsen; J Aldridge; K V Nielsen; M M Regan; K L Henriksen; A E Lykkesfeldt; S Müller; R D Gelber; K N Price; B B Rasmussen; G Viale; H Mouridsen Journal: Ann Oncol Date: 2011-10-10 Impact factor: 32.976
Authors: M Oberländer; H Alkemade; S Bünger; F Ernst; C Thorns; T Braunschweig; J K Habermann Journal: Pathol Oncol Res Date: 2014-03-07 Impact factor: 3.201
Authors: Gertraud Maskarinec; Eva Erber; Martijn Verheus; Brenda Y Hernandez; Jeffrey Killeen; Suzanne Cashin; J Mark Cline Journal: Nutr Cancer Date: 2009 Impact factor: 2.900
Authors: Lesley A Stead; Timothy L Lash; Jerome E Sobieraj; Dorcas D Chi; Jennifer L Westrup; Marjory Charlot; Rita A Blanchard; John C Lee; Thomas C King; Carol L Rosenberg Journal: Breast Cancer Res Date: 2009-03-25 Impact factor: 6.466
Authors: Anne E Lykkesfeldt; Katrine L Henriksen; Birgitte B Rasmussen; Hironobu Sasano; Dean B Evans; Susanne Møller; Bent Ejlertsen; Henning T Mouridsen Journal: BMC Cancer Date: 2009-06-16 Impact factor: 4.430
Authors: Martijn Verheus; Gertraud Maskarinec; Eva Erber; Jana S Steude; Jeffrey Killeen; Brenda Y Hernandez; J Mark Cline Journal: BMC Cancer Date: 2009-06-13 Impact factor: 4.430